HK Stock Market Move | ASCLETIS-B (01672) rose more than 3%, planning to discount about 4% of the stock rights issue, with a net raise of approximately HK$8.353 billion.

ASCLETIS-B (01672) rose more than 3%, and as of the time of writing, it rose 2.05%, to 12.95 Hong Kong dollars, with a turnover of 661,600 Hong Kong dollars. In terms of news, ASCLETIS-B announced that on February 3, 2026, the company plans to issue 69.256 million shares, accounting for approximately 6.98% of the total number of shares issued by the company as of the date of this announcement (9.92 billion shares, excluding 7.0842 million treasury shares). The issue price per share is 12.18 Hong Kong dollars, representing a discount of approximately 4.0% from the closing price of 12.69 Hong Kong dollars per share on February 2. The total expected proceeds from the placement are approximately 8.435 billion Hong Kong dollars, with expected net proceeds of approximately 8.353 billion Hong Kong dollars. It is proposed that approximately 90% of the net proceeds from the placement be used for the preparation, groundwork, and launch of the global Phase III clinical trial of ASC30, a small molecule oral GLP-1 receptor agonist for the treatment of obesity, while approximately 10% of the net proceeds from the placement be used for working capital and other general corporate purposes.